Emerald Health
London-based preventive health startup combining blood testing, AI, and GP care for proactive health monitoring.
Website: https://withemerald.com
Cover Block
From the public record
| Field | Value |
|---|---|
| Name | Emerald Health |
| Tagline | London-based preventive health startup combining blood testing, AI, and GP care for proactive health monitoring [Tech Funding News, October 2026] |
| Headquarters | London, UK [Tech Funding News, October 2026] |
| Founded | 2024 [Tech Funding News, October 2026] |
| Stage | Seed [Tech Funding News, October 2026] |
| Business model | Direct-to-consumer [Tech Funding News, January 2026] |
| Industry | Healthtech [Tech Funding News, October 2026] |
| Technology | AI / machine learning [Tech Funding News, January 2026] |
| Geography | Western Europe [Tech Funding News, October 2026] |
| Growth profile | Venture scale [Tech Funding News, October 2026] |
| Founding team | Alexander Badalyan, Anton Shchipanov, Dr. Dan McNally [Tech Funding News, May 2025] |
| Funding label | Seed, total disclosed £2.9 million [Tech Funding News, October 2026] |
Links
From the public record
- Website: https://withemerald.com
- App Store: https://podcasts.apple.com/be/podcast/emerald-health-podcast/id1887070190
The Short Version
PUBLIC Emerald Health is building a consumer preventive-health service that pairs clinic-based blood testing with software and GP follow-through, a model that deserves attention because the company has moved from launch to £2.9 million in total reported funding within roughly eighteen months of founding and is already operating across more than 50 UK testing locations, according to Tech Funding News [Tech Funding News, October 2026] [Tech Funding News, January 2026]. The founding story is unusually direct: the team reportedly began with a premium credit-card concept, then shifted into health after customer feedback pointed more clearly toward screenings and GP access, a pivot that matters because it suggests the present product was shaped by observed demand rather than abstract category enthusiasm [Tech Funding News, May 2025].
The service, as publicly described, combines blood testing across more than 115 biomarkers, centralized health data, AI-generated alerts, and an assigned GP who can diagnose, prescribe, and refer into private or NHS care; the practical wedge is not the model layer alone, but the link between diagnostic signal and clinical action [Tech Funding News, January 2026] [Tech Funding News, October 2026]. Company materials and investor posts add that memberships include two in-clinic screenings, live-chat GP access, and a personalized action plan, though those details are less independently corroborated than the financing and footprint data [LinkedIn] [Emerald].
The team reads as commercially credible for an early UK healthtech: co-founder and CEO Alexander Badalyan previously co-founded Mashroom, co-founder and CTO Anton Shchipanov previously developed software at Revolut, and co-founder Dr. Dan McNally is an NHS doctor who Tech Funding News reported also advised healthtech companies at Oliver Wyman [Crunchbase] [Tech Funding News, May 2025] [Emerald]. Head of AI Nazar Beknazarov's prior work at Toloka is directionally relevant if Emerald's product increasingly depends on longitudinal interpretation and member engagement software rather than one-off test reporting [LinkedIn, January 2024] [Tech Funding News, May 2025].
On capital formation, the public record shows an initial £625,000 angel round in May 2025, a $1.2 million pre-seed led by Boost Capital Partners in January 2026, and a £1.4 million round reported in October 2026, with total funding cited at £2.9 million by that point [Tech Funding News, May 2025] [Tech Funding News, January 2026] [Tech Funding News, October 2026]. The business model is direct to consumer rather than enterprise-led, which can produce faster product feedback loops but will put pressure on Emerald to prove repeat engagement, member acquisition efficiency, and that clinical operations can scale without eroding service quality [Tech Funding News, January 2026].
Over the next 12 to 18 months, the main public markers to watch are whether the company can convert location coverage into visible member growth, whether GP-enabled care translates into a retention advantage over test-only offerings, and whether Emerald's stated ambition to reach one million members remains aspirational or starts to show measurable evidence [Tech Funding News, October 2026]. At this stage, the interest is real, but so is the diligence burden: much of the product promise is clear, while the harder commercial proof points, especially retention, unit economics, and clinical throughput, are not yet established in public sources.
Single-source, plausible -- Core funding, location footprint, and team background are supported by Tech Funding News, Crunchbase, LinkedIn, and company pages, but several product-detail claims remain company-sourced or lightly corroborated.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | Direct-to-Consumer (DTC) |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (3+) |
| Funding | Total disclosed approximately $3,680,000 |
The Company in Brief
PUBLIC
Emerald Health presents as a London preventive health company built around a simple consumer promise: turn routine screening data into an ongoing care relationship rather than a one-off test result. Public company materials identify the business as London-based, founded in 2024, with Alexander Badalyan as co-founder and CEO, Anton Shchipanov as CTO, and Dr. Daniel McNally as CMO [RocketReach, Retrieved 2026] [Emerald] [Crunchbase, Retrieved 2026].
The public record on the founding story is thinner than the operating narrative now visible on the website. Emerald's own pages show a preventive-health service centered on biomarker testing, longitudinal health tracking, and clinical interpretation, including pages describing what is included in membership and how biomarkers are organized for members [Emerald] [Emerald]. Those materials establish the company's direction and product framing, but they do not, on their own, resolve legal entity details or a fuller incorporation history.
What can be said with confidence is chronological rather than expansive. Emerald was founded in 2024, and by the time of the retrieved public profiles and website materials in 2026, the company was presenting a named leadership team and a live consumer-facing preventive care offer from its London base [RocketReach, Retrieved 2026] [Emerald] [Crunchbase, Retrieved 2026]. For investors, that leaves the overview legible at the company-and-team level, while legal structure and early corporate milestones still warrant direct diligence.
Single-source, plausible -- This section is grounded in public company materials plus Crunchbase and RocketReach for founder role corroboration, but legal entity details and fuller milestone history are not established in the cited sources.
What They Have Built
Mixed sourcing
Emerald is not selling a standalone lab result or a generic wellness app. The product, as described in press coverage and on the company’s own site, is a preventive health membership that combines clinic-based blood testing, ongoing data review, and access to a GP who can act on findings rather than simply display them [Tech Funding News, January 2026] [Tech Funding News, October 2026]. Reported member features include testing across more than 115 biomarkers at more than 50 UK locations [PUBLIC] [Tech Funding News, January 2026], plus an assigned GP who can diagnose, prescribe, and refer patients to private or NHS care [PUBLIC] [Tech Funding News, October 2026]. A LinkedIn post from investor Jane Austin describes the membership as including two full-body clinic screenings, live-chat GP access, centralized health data, and a personalized action plan [PUBLIC] [LinkedIn].
The technical layer appears to sit between data aggregation and clinical triage, but the public record is still thin on implementation detail. Tech Funding News reports that Emerald combines blood testing with wearable and health-history inputs to generate AI alerts [PUBLIC] [Tech Funding News, January 2026], while the company website describes personalized insights, advanced tests, and expert guidance rather than publishing a detailed model architecture or validation framework [PUBLIC] [Emerald]. On the biomarker side, Emerald says its reports explain each marker, normal ranges, and the significance of outlier results [PUBLIC] [Emerald]. That points to a consumer health workflow built around interpretation and follow-up, with the stronger differentiation resting on clinician access and service integration than on any disclosed proprietary model claim [Tech Funding News, January 2026] [Emerald].
Unconfirmed -- Core product claims rely materially on company-owned pages and a LinkedIn post, with partial corroboration from Tech Funding News but limited independent technical verification.
Market Size and Demand
PUBLIC
Preventive health sits in a market that matters now because consumers are buying more care outside the traditional primary-care pathway, while founders and investors are testing whether diagnostics, software, and clinician access can be bundled into a recurring health membership [Tech Funding News, January 2026] [Tech Funding News, October 2026].
The available public record does not support a clean TAM, SAM, or SOM build for Emerald specifically, and no named third-party market report is present in the source set. What the sources do establish is narrower and still useful: Emerald is positioning into the overlap of direct-to-consumer diagnostics, longitudinal health tracking, and private GP-led preventive care in the UK [Tech Funding News, January 2026] [Emerald] [LinkedIn]. That matters because the product is not selling a single blood test in isolation. It is selling an ongoing interpretation and action loop, with testing, data aggregation, AI-generated alerts, and clinician follow-through presented as one service [Tech Funding News, January 2026] [Tech Funding News, October 2026].
Demand drivers in the public evidence are mostly product-structure signals rather than market-size figures. Emerald reported more than 50 UK testing locations by January 2026, which suggests management sees geographic access as a prerequisite for consumer adoption rather than a later expansion step [Tech Funding News, January 2026]. The service also covers more than 115 biomarkers and assigns members a GP who can diagnose, prescribe, and refer, which points to a broader consumer proposition: users are paying for continuity and interpretation, not just data generation [Tech Funding News, January 2026] [Tech Funding News, October 2026].
The adjacent markets are easier to define than the core one. On one side sit conventional private GP services and telehealth memberships, where the value proposition is clinician access and treatment. On the other sit diagnostics and biomarker panels, where the value proposition is visibility into health signals. Emerald appears to be trying to capture spend that might otherwise go separately to annual checkups, private blood testing, wearable subscriptions, and intermittent specialist consultations [Tech Funding News, January 2026] [Emerald] [LinkedIn].
Regulation and macro conditions cut both ways. The supportive case is straightforward: preventive health has intuitive consumer appeal, and a service that routes abnormal findings to licensed clinicians is easier to understand than an AI-only health product [Tech Funding News, January 2026] [Tech Funding News, October 2026]. The constraint is equally clear. Any model that touches diagnosis, prescribing, and referrals carries tighter clinical and operational requirements than a software-only wellness product, which means scaling demand does not automatically translate into low-friction expansion [Tech Funding News, October 2026]. Emerald's stated ambition to reach 1 million members underscores the size of the aspiration, but that target remains a company claim rather than market proof [Tech Funding News, October 2026].
| Market lens | Public evidence | Read-through |
|---|---|---|
| Core category | Preventive health membership combining blood testing, AI alerts, and GP care [Tech Funding News, January 2026] [Tech Funding News, October 2026] | Suggests a blended care-and-diagnostics market rather than a single-category software play |
| Access footprint | More than 50 UK testing locations by January 2026 [Tech Funding News, January 2026] | Indicates physical coverage is central to distribution and usability |
| Service depth | More than 115 biomarkers covered [Tech Funding News, January 2026] | Points to a broad screening offer intended to support repeat monitoring |
| Monetization posture | Membership includes screenings, GP access, centralized data, and action plans [LinkedIn] [Emerald] | Implies recurring consumer spend is the intended economic model |
The evidence supports a category bet on integrated preventive care, but not a quantified market-sizing claim. For now, the market case rests less on published TAM math and more on a visible consumer shift toward paying for faster, more continuous health oversight outside standard NHS pathways, as reflected in Emerald's product design and funding narrative [Tech Funding News, January 2026] [Tech Funding News, May 2025].
Unconfirmed -- This section relies primarily on company-linked materials and Tech Funding News coverage; no independent third-party market report in the provided source set supports quantified TAM, SAM, or SOM claims.
Who Else Is Fighting for This
Who Else Is Fighting for This
MIXED Emerald is positioning itself between at-home wellness testing and traditional primary care, with the bet that a paid membership can matter more if biomarker screening is paired with a GP who can actually diagnose, prescribe, and refer rather than simply generate alerts [Tech Funding News, January 2026] [Tech Funding News, October 2026].
The public record does not name direct startup competitors, so the competitive map has to be drawn by segment rather than by a verified peer set. On one side sit incumbent care pathways, chiefly NHS primary care and private GP services, which already own the clinical relationship and referral authority that Emerald is trying to package into a proactive format [Tech Funding News, October 2026]. On another side sit diagnostic and health-tracking substitutes, including standalone blood testing, wearables, and health dashboards, which can surface signals but, based on Emerald's own positioning, do not by themselves complete the care loop from abnormal result to medical action [Tech Funding News, January 2026] [Emerald]. A third lane is emerging preventive-health memberships, where the product is less a single test and more a recurring interpretation layer across testing, history, and clinician access, although the available sources do not establish which named companies Emerald meets most often in market [Tech Funding News, May 2025].
Emerald's present edge looks real, but narrow. The strongest public evidence is product design rather than distribution power: more than 115 biomarkers, more than 50 UK testing locations, and assigned GP access create a fuller offering than a one-off lab panel or a dashboard-only service [Tech Funding News, January 2026] [Tech Funding News, October 2026]. The founding mix also fits the product thesis, with software leadership from Anton Shchipanov, clinical credibility from Dr. Dan McNally, and AI depth signaled by Nazar Beknazarov's prior work at Toloka [Tech Funding News, May 2025] [LinkedIn, January 2024]. That said, this edge is still perishable. Testing-location access can be replicated if rivals secure similar lab relationships, and GP-enabled care is operationally harder than software but not structurally protected by the funding base disclosed so far, which stands at £2.9 million by October 2026 [Tech Funding News, October 2026].
The company's main exposure is that it does not appear to own the lowest-cost channel or the default patient relationship. Incumbent GPs and established care providers already have trust, repeat contact, and regulatory familiarity, while consumer health apps and wearables can acquire attention more cheaply and more frequently than a clinic-centered membership model can [Tech Funding News, October 2026]. Emerald also seems dependent on a premium, engaged consumer who will pay for preventive monitoring before an acute need arises, and the public sources do not yet show employer distribution, insurer distribution, or health-system partnerships that could widen reach or lower acquisition costs [Tech Funding News, January 2026] [Tech Funding News, October 2026]. In practice, that leaves Emerald exposed both upward to full-service private care groups and downward to cheaper testing or tracking substitutes.
Over the next 18 months, the most plausible competitive scenario is bifurcation. The winner if clinical follow-through proves to be the deciding purchase criterion is Emerald itself, because its assigned-GP model is the clearest publicly documented differentiation in the current record [Tech Funding News, October 2026]. The loser if consumers decide that monitoring without care is sufficient would be standalone testing and dashboard products as a category, because Emerald's product is explicitly built around the view that AI-only interpretation lacks medical nuance [Tech Funding News, January 2026]. The reverse is also true, and it is the more material risk for Emerald: if consumers prove price-sensitive and use preventive health episodically rather than as a membership, clinic-plus-GP offerings lose ground to simpler test-and-track substitutes. Public evidence is not yet enough to say which behavior is winning.
Unconfirmed -- This section relies on public product and funding reporting from Tech Funding News, plus company website material for service framing.
Opportunity
PUBLIC
The prize here is not a better blood test subscription, it is a chance to become a consumer health operating layer that sits between diagnostics, longitudinal data, and clinical action in a market where most offerings stop at one of those steps [Tech Funding News, January 2026] [Tech Funding News, October 2026].
The headline opportunity is straightforward. If Emerald can keep stitching together testing, interpretation, and GP follow-through in one paid membership, it has a path to become a scaled preventive care platform for consumers who want recurring monitoring rather than episodic checkups [Tech Funding News, January 2026] [LinkedIn]. That outcome is reachable, not merely aspirational, because the public record already shows three ingredients that usually do not appear together this early: a national testing footprint of more than 50 UK locations, a broad biomarker panel of more than 115 markers, and an assigned-GP model that can diagnose, prescribe, and refer rather than simply generate reports [Tech Funding News, January 2026] [Tech Funding News, October 2026]. The founding mix also fits the product claim. Emerald combines consumer startup experience, software execution, and a clinical lead with NHS and advisory background, which matters in a category where pure software products often struggle to convert insight into action [Tech Funding News, May 2025] [Crunchbase] [Emerald].
The upside can be framed as a small set of concrete scale paths rather than a single binary bet.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| UK preventive care brand | Emerald becomes a recognized paid membership for recurring preventive monitoring in the UK, with testing, interpretation, and GP care bundled into a single consumer product | Wider distribution across its existing 50-plus testing locations and repeat usage around scheduled screenings [Tech Funding News, January 2026] | The company already offers two clinic screenings, centralized health data, and GP access in one package, which supports recurring engagement rather than one-off transactions [LinkedIn] [Emerald] |
| Clinical action layer for diagnostics | Emerald turns biomarker data into a higher-value care workflow, where alerts lead directly to prescriptions, referrals, and care plans | Product improvements that tighten the loop between AI alerts and clinician action [Tech Funding News, January 2026] [Tech Funding News, October 2026] | Public sources already describe the service as combining AI-generated alerts with assigned GP care, which is a narrower but potentially stickier wedge than diagnostics alone [Tech Funding News, January 2026] [Tech Funding News, October 2026] |
| Consumer health data platform | Emerald builds a longitudinal member dataset across bloods, wearables, and health history that improves personalization and retention over time | Continued member growth and repeated testing cycles that expand the historical record for each user [Tech Funding News, January 2026] | The product is explicitly described as integrating clinic blood testing, wearable data, and health history into one preventive service, which is the raw material for cumulative personalization if retention holds [Tech Funding News, January 2026] [Emerald] |
The compounding mechanism, if it works, is not a classic social network effect. It is a data-and-care flywheel. Each additional member adds recurring biomarker history, wearable inputs, and observed clinical follow-up, which can make future alerts more context-aware and the action plan more useful at the next screening cycle [Tech Funding News, January 2026] [Emerald]. Each successful intervention then increases the value of keeping records, messaging, and GP access inside one system rather than splitting diagnostics, interpretation, and treatment across separate vendors [LinkedIn] [Tech Funding News, October 2026]. The early signs are still thin, but the product architecture already points in that direction: Emerald is selling ongoing membership, not a one-time test, and the service design centers on repeated screenings plus continuous access to care [LinkedIn] [Emerald].
The size of the win is easiest to think about through strategic position rather than current scale, because no public market sizing or revenue figure is available in the source set. In a strong case, Emerald could grow into a meaningful consumer preventive-health platform in the UK and adjacent markets, valuable because it owns the relationship across testing, interpretation, and action rather than any single step. The company's stated ambition to reach 1 million members is company-linked and unverified, so it is better treated as directional rather than evidentiary support [Tech Funding News, October 2026]. Even so, if the company proves durable recurring demand for high-frequency preventive monitoring and keeps clinical action inside the same loop, that would support venture-scale outcomes well beyond a niche diagnostics service (scenario, not a forecast) [Tech Funding News, January 2026] [Tech Funding News, October 2026].
Single-source, plausible -- This section relies primarily on Tech Funding News reporting, with partial corroboration from Emerald's website, LinkedIn, and Crunchbase for product structure and team roles.
Sources
From the public record
[Tech Funding News, October 2026] Ex-Revolut founders’ preventive health startup Emerald hits £2.9M total funding, targets 1M members | https://techfundingnews.com/emerald-raises-1-4m-preventive-health-innovate-uk-boost-capital/
[Tech Funding News, January 2026] Exclusive: Emerald closes $2M pre-seed to blend blood testing, AI, and medical care | https://techfundingnews.com/emerald-2m-pre-seed-gp-ai-preventive-health/
[Tech Funding News, May 2025] Ex-Revolut and NHS team launches Emerald with £625K to unite health data into one AI-powered preventive plan | https://techfundingnews.com/exclusive-ex-revolut-and-nhs-team-launches-emerald-with-625k-to-unite-health-data-into-one-ai-powered-preventive-plan/
[LinkedIn, January 2024] Toloka on LinkedIn: Data labeling for Generative AI and LLM | https://www.linkedin.com/posts/toloka_data-labeling-for-generative-ai-and-llm-activity-7152691240348655617-Gr9m
[Crunchbase, Retrieved 2026] Alexander Badalyan - CFO and Co-Founder @ Mashroom | https://www.crunchbase.com/person/alexander-badalyan
[RocketReach, Retrieved 2026] Alexander Badalyan Email & Phone Number | Emerald Co-Founder, CEO Contact Information | https://rocketreach.co/alexander-badalyan-email_32405020
Articles about Emerald Health
- A London Startup Is Blending AI Alerts With Assigned GP Care — The London startup has raised £2.9 million to combine high-volume biomarker screening with a clinician who can diagnose and prescribe.